Association of ALOX5AP1 SG13S114T/A variant with ischemic stroke, stroke subtypes and aspirin resistance

Sharma, Vandana; Dadheech, Sneha; Kaul, Subhash; Jyothy, A.; Munshi, Anjana

doi:10.1016/j.jns.2013.05.024

Cited by 13 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty studies provided summaries of data on the ALOX5AP rs10507391 polymorphism 13–18,20,22,23,25,26,28,29,31,32,34–38. Random-effects meta-analysis indicated no association of the polymorphism with IS in the overall population (OR=1.03 for A allele vs T allele; 95% CI: 0.93–1.14; P =0.557) (Figure 2A; Table 2).…”

Section: Resultsmentioning

confidence: 99%

Lack of association between ALOX5AP genetic polymorphisms and risk of ischemic stroke: evidence from meta-analyses

Zheng¹,

Ning²,

Xu³

et al. 2019

NDT

View full text Add to dashboard Cite

BackgroundIn recent years, there has been substantial research evaluating the relationship between arachidonate 5-lipoxygenase-activating protein (ALOX5AP) polymorphisms and ischemic stroke (IS). The objective of this study was to systematically review and analyze the existing evidence.MethodsA comprehensive search of major electronic databases for studies published between 1990 and 2018 was carried out. Data were synthesized as OR and 95% CI using fixed-effects and random-effects models.ResultsA total of 30 studies were available for analysis. The aggregate sample size across all studies was 32,782 (16,294 cases and 16,488 controls). We found no association of the ALOX5AP rs10507391 (OR=1.03 for A allele vs T allele; 95% CI: 0.93–1.14; P=0.557), rs4769874 (OR=1.13 for A allele vs G allele; 95% CI: 1.00–1.28; P=0.050), rs9551963 (OR=1.03 for A allele vs C allele; 95% CI: 0.96–1.11; P=0.372), rs17222814 (OR=1.09 for A allele vs G allele; 95% CI: 0.96–1.24; P=0.195), rs17222919 (OR=0.89 for G allele vs T allele; 95% CI: 0.75–1.06; P=0.175), and rs4073259 (OR=1.20 for A allele vs G allele; 95% CI: 1.00–1.45; P=0.056) polymorphisms with IS risk. Haplotype analysis also did not yield significant findings for the HapA (rs17222814G–rs10507391T–rs4769874G–rs9551963A; OR=1.20; 95% CI: 0.91–1.56; P=0.192) and HapB (rs17216473A–rs10507391A–rs9315050A–rs17222842G; OR=1.11; 95% CI: 0.90–1.38; P=0.339) haplotypes.ConclusionCurrent evidence does not support an association of rs10507391, rs4769874, rs9551963, rs17222814, rs17222919, rs4073259, and HapA and HapB with IS risk.

show abstract

Section: Resultsmentioning

confidence: 99%

Lack of association between ALOX5AP genetic polymorphisms and risk of ischemic stroke: evidence from meta-analyses

Zheng¹,

Ning²,

Xu³

et al. 2019

NDT

View full text Add to dashboard Cite

show abstract

“…In the first, the patient is considered resistant if there is a negative outcome (death or stroke for example). 17 In the second, several types of tests can be used, such as PFA-100, Verify-Now Aspirin, TEG, PL-11 platelet analyzer, serum and urinary TXB2, LTA, and multiplate analyzer. However, it is important to highlight that the measurement of platelet response to aspirin is highly variable, likely due to differing dependence of the arachidonic acid pathway between techniques.…”

Section: Discussionmentioning

confidence: 99%

Impact of pharmacogenetics on aspirin resistance: a systematic review

et al. 2023

View full text Add to dashboard Cite

Background Pharmacogenetics promises better control of diseases such as cardiovascular disease (CVD). Acetylsalicylic acid, aspirin, prevents the formation of an activating agent of platelet aggregation and vasoconstriction, and it is used to prevent CVD. Nevertheless, patients may have treatment failure due to genetic variants that modify the metabolism of the drug causing aspirin resistance (AR). Objectives To realize a systematic literature review to determine the impact of genetic variants on AR. Methods Articles published in the MEDLINE/PubMed, Cochrane, Scopus, LILACS, and SCIELO databases were systematically screened. A total of 290 articles were identified and 269 articles were excluded because they did not comply with the previously established inclusion criteria. A total of 20 case-control studies and 1 cohort was included. Results The genetic variants rs1126643 (ITGA2), rs3842787 (PTGS1), rs20417 (PTGS2), and rs5918 (ITGB3) were the most studied. As for relevance, of the 64 genetic variants evaluated by the articles, 14 had statistical significance (p < 0.05; 95% confidence interval [CI]) in at least one article. Among them, the following have had unanimous results: rs1371097 (P2RY1), rs1045642 (MDR1), rs1051931 and rs7756935 (PLA2G7), rs2071746 (HO1), rs1131882 and rs4523 (TBXA2R), rs434473 (ALOX12), rs9315042 (ALOX5AP), and rs662 (PON1), while these differ in real interference in AR: rs5918 (ITGB3), rs2243093 (GP1BA), rs1330344 (PTGS1), and rs20417 (PTGS2). As study limitations, we highlight the nonuniform methodologies of the analyzed articles and population differences. Conclusion It is noteworthy that pharmacogenetics is an expanding area. Therefore, further studies are needed to better understand the association between genetic variants and AR.

show abstract

“…15 In ASA-nonresponsive patients, a sustained platelet aggregation/activation occurs, leading to a consistent prothrombotic status. [27][28][29][30] Leukotriene-based inflammation and arachidonic acid derivatives such as thromboxane A2 have been known to play a crucial role in atherosclerosis. 27 Our results suggest that in AIS, the ASA-nonresponsive status/platelet insensitivity may be influenced by the previous therapeutic control of the main risk factors of cerebrovascular disease.…”

Section: Discussionmentioning

confidence: 99%

Can the Previous Therapeutic Control of the Main Risk Factors of Cerebrovascular Disease Influence the Acetylsalicylic Acid–Nonresponsive Status in Acute Ischemic Stroke Patients? Results from a Portuguese Prospective Cohort Study

Freitas-Silva

Gonçalves²,

Medeiros

et al. 2015

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

Association of ALOX5AP1 SG13S114T/A variant with ischemic stroke, stroke subtypes and aspirin resistance

Cited by 13 publications

References 34 publications

<p>Lack of association between <em>ALOX5AP</em> genetic polymorphisms and risk of ischemic stroke: evidence from meta-analyses</p>

<p>Lack of association between <em>ALOX5AP</em> genetic polymorphisms and risk of ischemic stroke: evidence from meta-analyses</p>

Impact of pharmacogenetics on aspirin resistance: a systematic review

Can the Previous Therapeutic Control of the Main Risk Factors of Cerebrovascular Disease Influence the Acetylsalicylic Acid–Nonresponsive Status in Acute Ischemic Stroke Patients? Results from a Portuguese Prospective Cohort Study

Contact Info

Product

Resources

About